You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.
Informaticians from Georgetown and other major cancer centers expect their technology to bring precision oncology services to community hospitals and clinics.
Despite plenty of hype and some growing pains, artificial intelligence is starting to prove its value in academic and community cancer centers.
The California-based health system is expanding its partnership with clinical decision support vendor CancerIQ to integrate risk assessment into the Cerner EHR workflow.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
Japanese software giant NEC invests in AI-centric software company BostonGene to advance immuno-oncology and other targeted cancer treatments.
Symbolized by its first time exhibiting at HIMSS, Roche Diagnostics is using data to bridge the worlds of imaging, sequencing, diagnostics, drug discovery, and treatment.
City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.
The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.